NeoLumina BioScience Preparing to Begin a Phase 2 Clinical Trial of Innovative Psilocybin-Based Therapy for Binge Eating Disorder
VANCOUVER, BRITISH COLUMBIA / July 17, 2025 / NeoLumina BioScience Inc., a pioneering clinical-stage biopharmaceutical company dedicated to developing breakthrough treatments for mental health disorders using psychedelics, announces the progression of its groundbreaking natural psilocybin-based product candidate, as it prepares to commence a Phase 2 clinical trial targeting binge eating disorder (BED).
To facilitate the launch and execution of this critical clinical study, NeoLumina is seeking a seed-round funding of $5 million. This funding will enable the company to finalize FDA approvals necessary to initiate the Phase 2 trial by early 2026, with completion projected for late 2027. Thus far, all funding initiatives have been supported by the company’s founders and management.
Eating disorders are the deadliest category within mental health disorders, leading to one fatality every 52 minutes on a global scale. Binge eating disorder stands out as the most prevalent among these conditions, surpassing anorexia, and bulimia combined, and impacts over 150 million individuals worldwide. With a significant portion of BED sufferers—approximately 70%—being obese, and 80% experiencing comorbid psychiatric and physical conditions like anxiety, depression, hypertension, and diabetes, the need for innovative treatments is critical. Alarmingly, around 23% of individuals with BED have attempted suicide.
Currently, the only FDA-approved medication for BED is a central nervous system stimulant primarily used to treat attention deficit hyperactivity disorder in children and adults. Psilocybin, the active compound in NeoLumina’s lead product, has shown promising effects on brain regions implicated in eating disorders, and is a proprietary psilocybin-based candidate supported by many issued patents, and has already demonstrated positive outcomes in various Phase 1 and 2 trials for conditions such as depression, anxiety, and alcohol abuse.
NeoLumina’s esteemed management team, backed by decades of expertise in biomedical product development, is complemented by a world-class advisory board. Notable members include Mark Gold, MD, Distinguished Professor of Psychiatry at the University of Florida; Wendy Oliver-Pyatt, MD, Director of the International Association of Eating Disorder Professionals and author of “Questions and Answers on Binge Eating Disorder, A Guide for Clinicians”; and Michael Murray, ND, a leading global figure in natural medicine.
For more information, please contact:
Jeremy Baker – NeoLumina Bioscience Inc
+1 833-303-1883 email us here
Visit us on social media:
Facebook / Twitter / LinkedIn / Instagram
About NeoLumina BioScience Inc.
NeoLumina BioScience is dedicated to pioneering innovative psychedelic-based treatments for mental health disorders. Its mission is to leverage cutting-edge scientific research and proprietary technology to develop novel, effective, and safe therapies that transform lives worldwide.
Forward Looking Statements
To the extent statements contained in this news release are not descriptions of historical facts regarding NeoLumina Bioscience Inc. they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements.
